Document is current
Any future updates will be listed below
-
Authors
Fielden, John
Wiseman, Katherine
Torrecilla, Ignacio https://orcid.org/0000-0003-4283-0283
Li, Shudong
Hume, Samuel https://orcid.org/0000-0003-4417-0370
Chiang, Shih-Chieh
Ruggiano, Annamaria
Narayan Singh, Abhay
Freire, Raimundo https://orcid.org/0000-0003-4473-8894
Hassanieh, Sylvana
Domingo, Enric https://orcid.org/0000-0003-4390-8767
Vendrell, Iolanda
Fischer, Roman https://orcid.org/0000-0002-9715-5951
Kessler, Benedikt M. https://orcid.org/0000-0002-8160-2446
Maughan, Timothy S.
El-Khamisy, Sherif F. https://orcid.org/0000-0003-2721-7763
Ramadan, Kristijan https://orcid.org/0000-0001-5522-021X
-
Funding
Funding for this research was provided by:
RCUK | Medical Research Council (MC_EX_MR/K022830/1)
Cancer Research UK
European Molecular Biology Organization (ALTF 1109-2017)
- License Information
-
More Information
Article History
Received: 7 November 2019
Accepted: 16 February 2020
First Online: 9 March 2020
Competing interests
: The authors declare the following competing interests. K.R., J.F., and T.S.M., are inventors of, and Oxford Innovation Ltd. are holders of, a patent application for the use of SPRTN as a cancer biomarker. The remaining authors declare no competiting interests.
